High parity and hormonal contraception use as risk factors for cervical cancer in East Kalimantan

  • Swandari Paramita
  • Soetomo Soewarto
  • M. Aris A. Widodo
  • Sutiman B. Sumitro
Keywords: Cervical cancer, hormonal contraception, menarche, parity
Abstract viewed: 2077 times
PDF downloaded: 1126 times

Abstract

Aim: To find risk factors associated with cervical cancer.

Methods: This a case-control study conducted in A.W. Sjahranie County General Hospital at Samarinda East Kalimantan from January until July 2009. There were 58 patients for each case and control group. Variables in this study were age, menarche, menopause, age of first marriage, parity, spouse's smoking status, hormonal contraception use, type of hormonal contraception, duration of hormonal contraception, IUD (intra uterine device) contraception use and duration of IUD contraception.

Results: final data analysis shows that parity and duration of hormonal contraception use increased the risk of cervical cancer. Women who had 5-12 children than 0-4 children had 2.6-folds increased risk to be cervical cancer. Compared to women never use of hormonal contraception, those who ever had hormonal contraception for 1-4 years and 5-25 years had two time and 4.5 times increased risk to be cervical cancer respectively.

Conclusion: Cervical cancer screening recommended to be focused on high-risk groups, among others, women with the number of children born more than five people or women in particular users of hormonal contraception methods with a range of use more than five years. (Med J Indones 2010; 19:268-72)

References

  1. World Health Organization. World: Human Papillomavirus and Related Cancer, Summary Report Update 2010. Geneva:World Health Organization. 2010;8-14.

  2. World Health Organization. Indonesia: Human Papillomavirus and Related Cancer, Summary Report Update 2010. Geneva: World Health Organization. 2010;6-11.

  3. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis- role of parity, oral contraceptives, and tobacco smoking. JNCI Monographs. 2003;31: 20-8.

  4. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al. International agency for research on cancer, multicentric cervical cancer study group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC Multicentric Case-Control Study. Lancet. 2002;359:1085-92.

  5. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. International agency for research on cancer, ulticentric cervical cancer study group. Role of parity and human papillomavirus in cervical cancer: The IARC Multicentric Case-Control Study. Lancet. 2002; 359:1093-101.

  6. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. JNCI. 2006;98:303-15.

  7. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME et al. HPV co-factors related to the 272 Paramita et al. Med J Indones development of cervical cancer: results from a populationbased study in Costa Rica. Br J Cancer. 2001; 84: 1219-26.

  8. Thomas DB, Ray RM, Koetsawang A, Kiviat N, Kuypers J, Qin Q, et al. Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. Am J Epidemiol. 2001;153:723-31.

  9. Bayo S, Bosch FX, de Sanjose S, Munoz N, Combita AL, Coursaget P, et al. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol. 2002; 31: 202-9.

  10. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer. 2000;82:1332-8.

  11. De Boer MA, Vet JN, Aziz MF, Cornain S, Purwoto G, van den Akker BE, et al. Human papillomavirus type 18 and other risk factors for cervical cancer in Jakarta, Indonesia. Int J Gynecol Cancer. 2006;16:1809-14.

  12. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370: 1609-21.

  13. Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev. 2001;10:171-7.

  14. Vanakankovit N, Taneepanichskul S. Effect of oral contraceptives on risk of cervical cancer. J Med Assoc Thai. 2008;91:7-12.

Published
2010-11-01
How to Cite
1.
Paramita S, Soewarto S, Widodo MAA, Sumitro SB. High parity and hormonal contraception use as risk factors for cervical cancer in East Kalimantan. Med J Indones [Internet]. 2010Nov.1 [cited 2022Jan.20];19(4):268-72. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/414
Section
Community Research